Sunitinib in pancreatic neuroendocrine tumors. Clinical case
The article describes a rare clinical case. Progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal region was detected in a 33-year-old patient with G2 pancreatic neuroendocrine tumour (NET) 1.5 months after surgical...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5268 |
| Summary: | The article describes a rare clinical case. Progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal region was detected in a 33-year-old patient with G2 pancreatic neuroendocrine tumour (NET) 1.5 months after surgical treatment. The patient received targeted therapy with sunitinib, oral protein kinase inhibitor, at daily dose of 37.5 mg and biotherapy with lanreotide, an analogue of somatostatin, which is used as a monthly subcutaneous injection. A partial effect in the form of reduction of all previously identified metastatic foci was reported after 12 months of treatment. Magnetic resonance imaging (MRI) showed a full therapeutic effect after 17 months of co-use of two drugs. So far, the patient continues to receive treatment for 25 months. Complete resolution of metastatic lesions persists for 8 months. The article shows the possibility of increasing anti-tumour efficacy in using targeted therapy combined with somatostatin analogues. The combined use of sunitinib and lanreotide has a pronounced anti-tumour effect in the first line therapy for highly differentiated pancreatic NEO and is tolerated without significant toxicity. With long-term treatment, the ease of use and availability of the required dosage of Sunitinib-Nativ oral preparation and ready-to-use injection depot makes it possible to maintain a regular lifestyle, professional activity and do not affect significantly the patients’ quality of life. It is necessary to continue the study of this first-line therapy regimen for pancreatic NET under clinical protocols. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |